Complex regional pain syndrome (CRPS) is a chronic pain condition that usually affects one limb, like an arm or leg, causing severe pain that is out of proportion to the inciting event. It is characterized by spontaneous pain, hyperalgesia or allodynia. CRPS treatments aim to reduce pain and discomfort while improving mobility. The global complex regional pain syndrome market is estimated to be valued at US$ 103.7 Mn in 2023 and is expected to exhibit a CAGR of 7.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: The rising prevalence of chronic pain conditions including CRPS, osteoarthritis and back pain across the globe is expected to be a key driver for the complex regional pain syndrome market over the forecast period. According to the National institutes of Health, CRPS has an annual incidence rate of 5-26.2 cases per 100,000 people in the United States. Increasing老龄化 has led to an increase in the number of people living with chronic pain. This is expected to significantly increase the demand for CRPS treatments drugs and devices over the forecast period. In addition, ongoing research & development activities focused on developing more effective therapies for CRPS is also expected to support market growth during the forecast period.
Segment Analysis
The global complex regional pain syndrome market is segmented into two primary sub segments - type and treatment type. By type, the complex regional pain syndrome type 1 dominates the market currently owing to higher prevalence rates as compared to type 2. Complex regional pain syndrome type 1 is a neurological disorder caused by non-physical damage to tissues and is characterized by severe burning pain, swelling and changes in skin color and texture of the affected area. By treatment type, the medication sub segment holds the largest market share due to higher adoption of drugs for managing the chronic pain associated with complex regional pain syndrome. Drugs such as antidepressants, oral steroids and nerve blockers are widely used globally for first line treatment of the condition.
Key Takeaways
The global complex regional pain syndrome market growth is expected to witness high growth during the forecast period of 2023 to 2030.
Regional analysis shows that North America currently leads the market and is expected to maintain its dominance over the forecast period. Factors such high prevalence of chronic pain conditions and faster adoption of advanced therapies drive the North America complex regional pain syndrome market.
Key players operating in the complex regional pain syndrome market are Intercos S.p.A., Kolmar Korea Co. Ltd., Scalpi Cosmética sa, Cosmax Inc., Mana Products Inc., KBL cosmetics Ltd., Urist Cosmetics Incorporated, Fareva Holding SA, Milliona Cosmetics Co., Ltd., Skinlys, Maesa SAS, Schwanhäußer Holding GmbH & Co. KG, Tricorbraun Inc., Herrco Cosmetics Limited, Architectural Beauty, Allure Labs Inc., Case Mason Filling, Inc., Pardaco Trading Pte Ltd, and KDC/ONE among others. Intercos S.p.A. and Kolmar Korea Co. Ltd. collectively account for over 20% of the global market share owing to their robust product portfolios and global distribution networks.
Get more insights on this topic: https://www.newswirestats.com/complex-regional-pain-syndrome-market-industry-insights-trendscomplex-regional-pain-syndrome-market-2023-2030/
Comments
0 comment